华蟾素胶囊联合吡柔比星治疗晚期乳腺癌的临床研究

目的探讨华蟾素胶囊联合注射用吡柔比星治疗晚期乳腺癌的临床疗效。方法选取锦州医科大学附属第一医院在2015年10月—2017年10月接收的乳晚期腺癌患者120例作为研究对象,将所有患者随机分为对照组和治疗组,每组各60例。对照组静脉注射注射用吡柔比星50 mg/m2,1次/d;治疗组在对照组治疗的基础上口服华蟾素胶囊,4粒/次,3次/d。4周为1个疗程,两组患者均持续治疗2个疗程。观察两组患者的临床疗效,同时比较治疗前后两组患者生活质量评分、肿瘤标志物水平、副作用、复发率和生存率。结果治疗组患者客观缓解率(56.67%)显著高于对照组患者客观缓解率(46.67%),两组差异具有统计学意义(P0.05);治疗组患者临床控制率(78.33%)显著高于对照组患者临床控制率(68.33%),两组差异具有统计学意义(P0.05)。治疗后,两组患者生理状态评分、心理状态评分、躯体功能评分、社会功能评分均显著升高,两组差异具有统计学意义(P0.05);并且治疗组患者生活质量评分显著高于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组患者糖类抗原125(CA125)、糖类抗原153(CA153)和癌胚抗原(CEA)水平均显著降低,差异具有统计学意义(P0.05);并且治疗组肿瘤标志物水平显著高于对照组,两组比较差异具有统计学意义(P0.05)。对照组患者复发率(16.67%)显著高于治疗组患者复发率(5.00%),两组比较差异具有统计学意义(P0.05)。治疗组患者生存率(81.67%)显著高于对照组患者生存率(58.33%),两组比较差异具有统计学意义(P0.05)。结论华蟾素胶囊联合注射用吡柔比星治疗晚期乳腺癌具有较好的临床疗效,显著改善患者生活质量,改善患者相关肿瘤标志物水平,安全性较高,值得临床推广。

Clinical study of Huachansu Capsules combined with pirarubicin in treatment of advanced breast cancer

Objective To investigate the clinical effect of Huachansu Capsules combined with Pirarubicin for injection in treatment of advanced breast cancer. Methods Patients (120 cases) with advanced breast cancer in the First Affiliated Hospital of Jinzhou Medical University from April 2015 to April 2015 were randomly divided into control and treatment groups, and each group had 60 cases. Patients in the control group were iv administered with Pirarubicin for injection 50 mg/m², once daily. Patients in the treatment group were po administered with Huachansu Capsules on the basis of the control group, 4 grains/time, three times daily. One course of treatment had 4 weeks, and patients in two groups were treated for two courses. After treatment, the clinical efficacy was evaluated, and quality of life score, level of tumor markers, side effects, recurrence rate, and survival rate in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 46.67% and 56.67%, and there were differences between two groups (P<0.05). After treatment, the clinical control rate in the control and treatment groups were 68.33% and 78.33%, and there were differences between two groups (P<0.05). After the treatment, the quality of life scores of the two groups, such as physiological state score, psychological state score, physical function score, and social function score were significantly improved, and the difference between the two groups was statistically significant (P<0.05). And the improvement of quality of life score in treatment group was significantly higher than those in control group. After treatment, the levels of CA125, CA153, and CEA of two groups were significantly increased, and the difference was statistically significant (P<0.05). The levels of tumor markers in the treatment group were significantly higher than those in the control group, and the difference was statistically significant (P<0.05). The recurrence rate of control group (16.67%) was significantly higher than that of treatment group (5.00%), and the difference between two groups was statistically significant (P<0.05). The survival rate of treatment group (81.67%) was significantly higher than that of the control group (58.33%), and the difference between the two groups was statistically significant (P<0.05). Conclusion Huachansu Capsules combined with Pirarubicin for injection has good clinical curative effect in treatment of advanced breast cancer, can significantly improve the patients quality of life and levels of tumor markers, which has a certain clinical application value.